When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

By Akin Nazli in Belgrade Ugur Sahin, owner of BioNTech (Nasdaq/BNTX), has been ranked second in Forbes Turkey’s Top 100 ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Dr. Peter Marks, a Food and Drug Administration official who had a leading role in vaccine regulation, was ousted by Health and Human Services Secretary Robert F. Kennedy Jr., and alleged Kennedy was ...

May 5, 2025 BioNTech says Novartis executive Zapata-Gomez to become CFO German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

Revenues during the first quarter of 2025 were mainly driven by revenues derived from BioNTech’s COVID-19 vaccine collaboration. Cost of sales were €83.8 million for the three months ended ...

German biotech BioNTech (Nasdaq: BNTX) saw its shares dip 3.4% to $101.44 today, after it reported financial results for the ...